Autumn Research Update Meeting 2025
Our 2025 Autumn Research Update Meeting will take place once again at the renowned Royal Society of Medicine (RSM), Wimpole Street, London, on Monday 10 November, where guests can look forward to an engaging agenda featuring the latest updates from our funded research. Theme: Revolutionising...
Learn more
UDCA and laboratory cell-based Parkinson’s
There is a great deal of variability between individuals with Parkinson’s in terms of features like symptoms and speed of disease progression. Given these differences, many researchers believe that we may not be dealing with a single condition, but rather a ‘syndrome’ – that is,…
The Minnesota UDCA clinical study
Researchers in Minnesota (USA) have recently published the results of a small pilot clinical trial investigating the safety of Ursodeoxycholic acid (or UDCA) in Parkinson’s. Currently UDCA is used to treat gallstones but research has gradually been building that suggests this medication could potentially be…
GDNF and cell transplantation: dual therapies for Parkinson’s
Parkinson’s is a complex condition and it is becoming increasingly clear that the future of disease-modifying therapies for Parkinson’s will rely on the use of multiple treatment approaches, as opposed to a single therapy. Scientists in Australia have recently published pre-clinical research exploring this idea…
Similarities between Alzheimer’s and Parkinson’s
Recently, two research groups independently published journal articles suggesting that a genetic variation associated with Alzheimer’s might also have an important influence in Parkinson’s and related conditions. The scientists found that a protein called Apolipoprotein E (or ApoE) can affect the severity of the toxic accumulation…
New developments in diabetes drugs for Parkinson’s
At the forefront of treatments for diabetes is a class of drug called glucagon-like peptide 1 receptor (or GLP-1R) agonists. There is also now considerable laboratory research that suggests GLP-1R diabetes drugs could potentially be used in the treatment of Parkinson’s. An agonist is a drug that…